News and Resources

Dexpramipexole Kv 7 Company News
04.24.19

Knopp Biosciences Receives FDA Orphan Drug Designation for Dexpramipexole for Treatment of Hypereosinophilic Syndrome

Discover this News
03.20.19

Knopp Biosciences Enters Collaboration with Leading UK Investigators to Commence Phase 2 Clinical Trial of Dexpramipexole in Severe Eosinophilic Asthma

Discover this News
03.18.19

CEO Dr. Michael Bozik’s interview with “The Heartbeat of Main Street” with Bank of America and ForbesBooks

Discover this News
01.31.19

Knopp Biosciences’ Rachel Kopper Elected National President of Women In Bio

Discover this News
01.16.19

Knopp Biosciences Expands Research Collaboration with Cincinnati Children’s to Characterize Effect of Dexpramipexole in Inflammatory Diseases

Discover this News
11.21.18

Knopp Biosciences to Present at the Piper Jaffray 30th Annual Healthcare Conference

Discover this News
05.22.18

NIAID Now: Repurposed Drug Shows Promise for Treating Rare Eosinophilic Diseases

Discover this News
10.23.17

Knopp Biosciences Announces Renewal of NIH Blueprint Grant Award for Advancing KCNQ2 Modulators in Epilepsy

Discover this News
09.06.17

Knopp Biosciences and APFED Announce Partnership to Advance Awareness of Hypereosinophilic Syndromes

Discover this News
1 2 3